Priveterra Acquisition announced the completion of its business combination with AEON Biopharma, a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions.
After adjourning the shareholder vote eight times, the SPAC poured an additional $125 million into the deal, providing more than enough financing to cover the minimum cash condition.
Latham & Watkins served as legal advisors to AEON. Davis Polk & Wardwell served as legal advisors to Priveterra. Cohen & Company Capital Markets was sole financial advisor to Priveterra. Roth Capital Partners served as capital markets advisor to Priveterra. Read more.
